{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:55:15Z","timestamp":1781769315018,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-026-07037-8","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:15:44Z","timestamp":1778217344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of telitacicept in IgA vasculitis nephritis: a single-center retrospective study"],"prefix":"10.1007","volume":"185","author":[{"given":"Tiantian","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaozhen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuguang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"issue":"1","key":"7037_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12519-014-0534-5","volume":"11","author":"JY Chen","year":"2015","unstructured":"Chen JY, Mao JH (2015) Henoch-Sch\u00f6nlein purpura nephritis in children: incidence, pathogenesis and management. World J Pediatr 11(1):29\u201334","journal-title":"World J Pediatr"},{"issue":"10","key":"7037_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2014.126","volume":"10","author":"JC Davin","year":"2014","unstructured":"Davin JC, Coppo R (2014) Henoch-Sch\u00f6nlein purpura nephritis in children. Nat Rev Nephrol 10(10):563\u2013573","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"7037_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","volume":"58","author":"Y Fan","year":"2022","unstructured":"Fan Y, Gao D, Zhang Z (2022) Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of Systemic Lupus Erythematosus. Drugs Today (Barc) 58(1):23\u201332","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"7037_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides [J]. Arthritis Rheum 65(1):1\u201311","journal-title":"Arthritis Rheum"},{"issue":"4","key":"7037_CR5","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.kint.2025.04.003","volume":"108","author":"J Floege","year":"2025","unstructured":"Floege J, Barratt J, Cook HT et al (2025) Executive summary of the KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV) [J]. Kidney Int 108(4):548\u2013554","journal-title":"Kidney Int"},{"issue":"5","key":"7037_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ki.2010.150","volume":"78","author":"E Pillebout","year":"2010","unstructured":"Pillebout E, Alberti C, Guillevin L et al (2010) Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Sch\u00f6nlein Purpura [J]. Kidney Int 78(5):495\u2013502","journal-title":"Kidney Int"},{"issue":"4","key":"7037_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00467-017-3846-6","volume":"33","author":"A Hackl","year":"2018","unstructured":"Hackl A, Becker JU, K\u00f6RNER LM et al (2018) Mycophenolate mofetil following glucocorticoid treatment in Henoch-Sch\u00f6nlein purpura nephritis: the role of early initiation and therapeutic drug monitoring [J]. Pediatric nephrology (Berlin, Germany) 33(4):619\u2013629","journal-title":"Pediatric nephrology (Berlin, Germany)"},{"key":"7037_CR8","unstructured":"Fenoglio R, Sciascia S, Naretto C et al (2020) Rituximab in severe immunoglobulin-A vasculitis (Henoch-Sch\u00f6nlein) with aggressive nephritis. Clin Exp Rheumatol 38 Suppl 124(2):195\u2013200"},{"issue":"1","key":"7037_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12969-018-0285-2","volume":"16","author":"CB Crayne","year":"2018","unstructured":"Crayne CB, Eloseily E, Mannion ML et al (2018) Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature [J]. Pediatr Rheumatol Online J 16(1):71","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"7037_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D et al (2024) Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 83(4):475\u2013487","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7037_CR11","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1093\/rheumatology\/keae601","volume":"64","author":"H Gao","year":"2025","unstructured":"Gao H, Lin J, Yang M et al (2025) Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study [J]. Rheumatology (Oxford) 64(5):2945\u20132952","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"7037_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000492237","volume":"149","author":"L Liu","year":"2025","unstructured":"Liu L, Liu Y, Li J et al (2025) Efficacy and safety of telitacicept in IgA nephropathy: a retrospective, multicenter study [J]. Nephron 149(1):1\u201310","journal-title":"Nephron"},{"issue":"3","key":"7037_CR13","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2023","unstructured":"Lv J, Liu L, Hao C et al (2023) Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney international reports 8(3):499\u2013506","journal-title":"Kidney Int Rep"},{"issue":"10","key":"7037_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae285","volume":"17","author":"M Wang","year":"2024","unstructured":"Wang M, Ma J, Yao L et al (2024) Efficacy and safety of telitacicept, a BLyS\/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study. Clin Kidney J 17(10):sfae285","journal-title":"Clin Kidney J"},{"issue":"9334","key":"7037_CR15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/S0140-6736(02)09835-5","volume":"360","author":"J Ronkainen","year":"2002","unstructured":"Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch-Sch\u00f6nlein purpura: a retrospective cohort study. Lancet (London, England) 360(9334):666\u201370","journal-title":"Lancet (London, England)"},{"issue":"10","key":"7037_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0223218","volume":"14","author":"D Shi","year":"2019","unstructured":"Shi D, Chan H, Yang X et al (2019) Risk factors associated with IgA vasculitis with nephritis (Henoch-Sch\u00f6nlein purpura nephritis) progressing to unfavorable outcomes: a meta-analysis [J]. PLoS ONE 14(10):e0223218","journal-title":"PLoS ONE"},{"issue":"12","key":"7037_CR17","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.autrev.2017.10.009","volume":"16","author":"MH Heineke","year":"2017","unstructured":"Heineke MH, Ballering AV, Jamin A et al (2017) New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Sch\u00f6nlein purpura) [J]. Autoimmun Rev 16(12):1246\u20131253","journal-title":"Autoimmun Rev"},{"key":"7037_CR18","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Rodr\u00edguez J, Carbonell C, Mir\u00f3n-Canelo JA et al (2020) Rituximab treatment for IgA vasculitis: a systematic review. Autoimmun Rev 19(4):102490","DOI":"10.1016\/j.autrev.2020.102490"},{"issue":"14","key":"7037_CR19","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Telitacicept: first approval. Drugs 81(14):1671\u20131675","journal-title":"Drugs"},{"key":"7037_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1423035","volume":"15","author":"C Fan","year":"2024","unstructured":"Fan C, Yang T, Zheng S et al (2024) Frequency and predictors for early-achieved Lupus low disease activity state in Systemic Lupus Erythematosus patients treated with telitacicept or belimumab: a real-life, single-center observational study. Front Immunol 15:1423035","journal-title":"Front Immunol"},{"key":"7037_CR21","doi-asserted-by":"publisher","first-page":"1268929","DOI":"10.3389\/fimmu.2023.1268929","volume":"14","author":"L Zhang","year":"2023","unstructured":"Zhang L, Jin H, Wang D et al (2023) Case report: successful treatment of refractory membranous nephropathy with telitacicept [J]. Front Immunol 14:1268929","journal-title":"Front Immunol"},{"key":"7037_CR22","doi-asserted-by":"publisher","first-page":"1298650","DOI":"10.3389\/fimmu.2023.1298650","volume":"14","author":"L Huang","year":"2023","unstructured":"Huang L, Lin W, Liu Y et al (2023) Combination treatment with telitacicept, cyclophosphamide and glucocorticoids for severe Granulomatous polyangiitis: a case report and literature review [J]. Front Immunol 14:1298650","journal-title":"Front Immunol"},{"issue":"6","key":"7037_CR23","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X et al (2021) Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol 43(6):666\u201373","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"4","key":"7037_CR24","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ekir.2024.01.003","volume":"9","author":"J Zan","year":"2024","unstructured":"Zan J, Liu L, Li G et al (2024) Effect of Telitacicept on circulating Gd-IgA1 and IgA-containing immune complexes in IgA nephropathy. Kidney Int Rep 9(4):1067\u201371","journal-title":"Kidney Int Rep"},{"issue":"8","key":"7037_CR25","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00467-025-06769-3","volume":"40","author":"Y Jin","year":"2025","unstructured":"Jin Y, Zhu J, Sheng A et al (2025) Telitacicept as a BAFF\/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis. Pediatric nephrology (Berlin, Germany) 40(8):2561\u20139","journal-title":"Pediatric nephrology (Berlin, Germany)"},{"key":"7037_CR26","doi-asserted-by":"publisher","first-page":"11207","DOI":"10.2147\/DDDT.S565279","volume":"19","author":"L Zhou","year":"2025","unstructured":"Zhou L, Yang F, Han Y et al (2025) Efficacy and safety of Telitacicept in IgA nephropathy and IgA vasculitis-associated nephritis in children: a retrospective single-centre study. Drug Des Devel Ther 19:11207\u201311216","journal-title":"Drug Des Devel Ther"},{"issue":"12","key":"7037_CR27","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1007\/s00467-025-06905-z","volume":"40","author":"J Wu","year":"2025","unstructured":"Wu J, Chen P, Liu L et al (2025) Efficacy and safety of telitacicept in IgA nephropathy and IgA vasculitis nephropathy in adolescents: A case series. Pediatric nephrology (Berlin, Germany) 40(12):3663\u201373","journal-title":"Pediatric nephrology (Berlin, Germany)"},{"issue":"4","key":"7037_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2174\/18756336MTA2lNDYc2","volume":"16","author":"AKC Leung","year":"2020","unstructured":"Leung AKC, Barankin B, Leong KF (2020) Henoch-Sch\u00f6nlein purpura in children: An updated review. Curr Pediatr Rev 16(4):265\u2013276","journal-title":"Curr Pediatr Rev"},{"key":"7037_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103291","volume":"148","author":"L Zeng","year":"2024","unstructured":"Zeng L, Yang K, Wu Y et al (2024) Telitacicept: a novel horizon in targeting autoimmunity and rheumatic diseases. J Autoimmun 148:103291","journal-title":"J Autoimmun"},{"key":"7037_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1694197","volume":"17","author":"H Li","year":"2026","unstructured":"Li H, Li W, Wang F et al (2026) Efficacy and safety of telitacicept in IgA nephropathy and its impact on urinary Gd-IgA1: Insights from a real-world study. Front Immunol 17:1694197","journal-title":"Front Immunol"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07037-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-07037-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07037-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:34:38Z","timestamp":1781768078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-026-07037-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["7037"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-07037-8","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"366"}}